- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

تسجيل اكثر من مليون اصابة بفيروس كورونا بالعالم
عدد الاصابات 1,000,168
عدد حالات الشفاء 210,191
عدد الوفيات 51,354


برنامج تطوير مهنة الصيدلة
https://news.1rj.ru/str/ppdprogram

‏صورة من Dr Mahmoud Alburyhi

‏صورة من Dr Mahmoud Alburyhi

‏صورة من Dr Mahmoud Alburyhi

كـاريكـاتـــير مكافحة الطواقم الطبية لفيروس كورونا

- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

✍معا - ضد- كورونا المستجد - كوفيد19:

(اللهم ارفع عن بلادنا الغلاء والبلاء و الوباء و انزل على عبادك السكينةوالطمأنينة).

بقلم: أ. د/محمود مهيوب البريهي

⏪رسالة إلى طلبة الكليات الطبية والمعاهد الصحية:

ان انتشار وباء كورونا المستجدفي العالم
يتطلب بذل كل الجهود المستمرة لمواجهة هذا الوباء ف العلماء والباحثين في مجال البحث للوصول الى الدواء او اللقاح ضد هذا الفيروس

والاطباء والصيادله وفريق الرعاية الصحية في العالم عليهم الرعاية الصحية والمتابعة والتوعية للمجتمع

و رسالتنا إلى طلبة الكليات الطبية والمعاهد الصحية بان عليهم إتباع التالي :

اولا: التاكد والحصول على مصادر المعلومات من وزارة الصحة والجهات المختصة ومنظمة الصحة العالمية

ثانيا:عدم ترويج الشائعات وعدم التهويل ونشر الخوف الذي يربك المجتمع اكثر من الوباء

ثالثا: العمل على التوعية المستمرة للمجتمع بإتباع جميع التعليمات الاحترازية منها النظافة وكل الممارسات التي تجنب المجتمع عدوى الوباء

رابعا: استخدام الوسائل العلمية في تطبيق التعليمات وتوصيل المعلومات والابتعاد عن العشوائية في التعليمات الوقائية من الوباء

خامسا: التسجيل مع فريق وزارة الصحة من اجل المساعده في الحالات الطارئة او اذا استدعت الضرورة لذلك

سادسا: المساهمة الفعالة في نشر الوعي بين طلبة الجامعات بمختلف الكليات كون طلبة الجامعات لهم دور فعال في توصيل الرسالة إلى كل المجتمع

سابعا: المساهمة الفعالة والتوعية للمجتمع والمشاركة مع كل الجهات التعليمية و التربوية والاعلامية والثقافية لتوصيل المعلومات الموثوقة من خلال التاكد منها من الجهات المختصة..

ثامنا: التعاون مع فريق الرعاية الصحية والعمل بروح الفريق الواحد محليا واقليميا ودوليا لمواجهة الوباء

تاسعا: المتابعة المستمرة لكل جديد عن الوباء وطرق مكافحته والوقاية منه وما توصل اليه العلم والعلماء للوقاية او العلاج من هذا الوباء كورونا المستجد.

*دمتم بصحة وعافية دائمة بإذن الله*


مدير برنامج تطوير مهنة الصيدلة
أ. د/محمود مهيوب البريهي
رئيس جامعة العطاء للعلوم والتكنولوجيا
أستاذ الصيدلانيات والصيدلة الصناعية
كلية الصيدلة جامعة صنعاء

10أبريل 2020م

برنامج تطوير مهنة الصيدلة
https://news.1rj.ru/str/ppdprogram

*30 ثانية تختصر شرح خطورة التواجد في الأماكن المزدحمة، وأهمية التباعد بين الافراد حاليا وذلك لمواجهة وباء #فيروس_كورونا.*

#الهيئة_العليا_للأدوية_والمستلزمات_الطبية #شارك_في_التوعية

مشاركة برنامج تطوير مهنة الصيدلة مع الاتحاد العالمي للصيادلة في حملة عالمية
ضد وباء كورونا كوفيد 19.

د.ص/محمود الاصبحي
مجال التثقيف الدوائي والصيدلاني
برنامج تطوير مهنة الصيدلة
https://news.1rj.ru/str/ppdprogram/2095

مشاركة برنامج تطوير مهنة الصيدلة مع الاتحاد العالمي للصيادلة في حملة عالمية
ضد وباء كورونا كوفيد 19.

د.ص/محمود الاصبحي
مجال التثقيف الدوائي والصيدلاني
برنامج تطوير مهنة الصيدلة
https://news.1rj.ru/str/ppdprogram/2095

*COVID-19 LATEST: "No evidence" to suggest NSAIDs increase severity of COVID-19*

➡️ Patients can take paracetamol or ibuprofen when self-medicating for symptoms of COVID-19, experts have concluded. The conclusion comes after the Commission of Human Medicines (CHM) and the National Institute for Health and Care Excellence (NICE) began reviewing evidence, on 17 March 2020, linking the use of non-steroidal anti-inflammatory drugs (NSAIDs) – including ibuprofen – to increased susceptibility of COVID-19 or the worsening of symptoms. The review, which concluded on 14 April 2020, found that evidence of a link was insufficient. CHM and NICE said in a joint letter that NSAIDs should be used at the “lowest effective dose for the shortest possible period” and that patients who have been prescribed NSAIDs as a treatment for a long-term condition, such as arthritis, should keep taking these medicines as normal. However, NICE said the review did not consider people who are taking NSAIDs long-term for existing chronic conditions.

➡️ According to NICE, the review identified 156 references, 13 of which were assessed for relevance by reviewers. “However, none were suitable for inclusion,” it said. “This means that no evidence from published scientific studies was found to determine whether acute use of NSAIDs is related to increased risk of developing COVID-19 or increased risk of a more severe illness.” It added that the evidence suggested that, although NSAIDs reduce acute symptoms, such as fever, they may mask symptoms of worsening acute respiratory tract infection, with further evidence needed to confirm if this applies to COVID-19.

🔎The Pharmaceutical Journal.
- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

▶️Using principles of evidence-based practice, pharmacists:

✅Collect
The pharmacist assures the collection of the necessary subjective and objective information about the patient in order to understand the relevant medical/ medication history and clinical status of the patient.

✅Assess
The pharmacist assesses the information collected and analyzes the clinical effects of the patient’s therapy in the context of the patient’s overall health goals in order to identify and prioritize problems and achieve optimal care.

✅Plan
The pharmacist develops an individualized patient-centered care plan, in collaboration with other health care professionals and the patient or caregiver that is evidence-based and cost-effective.

✅Implement
The pharmacist implements the care plan in collaboration with other health care professionals and the patient or caregiver.

✅Follow-up:
Monitor and Evaluate
The pharmacist monitors and evaluates effectiveness of the care plan and modifies the plan in collaboration with other health care professionals and the patient or caregiver as needed.

https://news.1rj.ru/str/ppdprogram

*SARS-CoV-2 can survive on some surfaces for days research reveals*

⏺️ Research published in the New England Journal of Medicine suggests that the virus that causes COVID-19 can remain viable on hard surfaces for up to 72 hours.

⏭️ The virus that causes COVID-19, SARS-CoV-2, can survive on some surfaces for a matter of days, a study published in the New England Journal of Medicine (17 March 2020) suggests.

🔰Researchers analysed the aerosol and surface stability of SARS-CoV-2 compared with that of the most closely related human coronavirus, SARS-CoV-1 — the virus that causes severe acute respiratory syndrome (SARS).

▶️ To do this, they carried out stability experiments in five environmental conditions; aerosol, plastic, stainless steel, copper and cardboard.

⏩ It was found that SARS-CoV-2 remained viable in aerosols for the duration of the three-hour experiment. The researchers also discovered that SAR-CoV-2 was more stable on plastic and stainless steel than on copper and cardboard, remaining viable for up to 72 hours after application onto these surfaces.

On copper and cardboard, the SARS-CoV-2 remained viable for around 4 hours and 24 hours, respectively.

➡️ Overall, the researchers found the stability of SARS-CoV-2 to be similar to that of SARS-CoV-1. This, they said, suggested that the reason SARS-CoV-2 had now spread further than SARS-CoV-1 could be the result of other factors, such as the potential for people infected with SARS-CoV-2 to shed and transmit the virus while remaining asymptomatic.

The researchers said that their study could “provide information for pandemic mitigation efforts”.

*References:
New England Journal of Medicine.

- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

*International Pharmaceutical Federation "FIP"*

➡️ Pharmacists should be central to future mass testing for, and vaccination against, COVID-19 the International Pharmaceutical Federation (FIP) has said.

➡️ In a statement issued on 14 April 2020, the FIP said that once evidence-based, rapid point-of-care tests for the illness ere available in the community, the pharmacy network should be authorised and harnessed to administer these.

➡️ Likewise, when COVID-19 vaccines are available, regulations should allow for pharmacists to vaccinate adults against the virus. “The valuable service that pharmacists and their teams provide to communities, and their important contribution to easing the huge strain being placed on health systems during the current coronavirus/COVID-19 pandemic is now clearer than ever”, said Dominique Jordan, president of the FIP.

🔎 FIP
- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

⏩Training on the Assessment of Drug Therapy Problems(Pharmaceutical Care) :

▶️Drug Therapy Problems

The pharmacist staff should be knowledgeable of the drug therapy problems in general
that are:

▶️• Adverse Drug Reactions

▶️• Choice of therapy,

▶️• Inappropriate indications:

▶️–drugs without indications

▶️–indications without drugs

▶️• Drug–Drug interactions,
and
▶️• Inappropriate Dosage adjustment:

▶️–underdose/overdose

▶️or–duplications

▶️• Compliance to therapy

https://news.1rj.ru/str/ppdprogram

*COVID-19 and Diabetes: Known Mechanisms and a 'New Beast'?*

➡️ Diabetes may be an independent risk factor for rapid progression and poor prognosis of COVID-19 through several known pathways and a possible new one: direct damage to pancreatic islets.

⏭️ As with nearly every finding related to the novel 2019 coronavirus disease, the evidence thus far comes primarily from case series and anecdotal reports, and as such has obvious limitations.

👉 In one of the latest case series, Chinese researchers compared 137 individuals without diabetes to 37 with diabetes, and then compared the subsets of those two groups without comorbidities (26 and 24 people, respectively).

▶️ In the latter comparison, those with diabetes still had a significantly greater risk of severe pneumonia, release of tissue injury-related enzymes, excessive uncontrolled inflammatory responses, and hypercoagulable state associated with dysregulated glucose metabolism, compared to those with no diabetes.

➡️ And those with diabetes also had higher levels of biomarkers suggesting an inflammatory "storm" preceding rapid deterioration of COVID-19, say Weina Guo, of Huazhong University of Science and Technology, Wuhan, China, and colleagues in their article, published online March 31 in Diabetes Metabolism Research and Reviews.

🔰While results of this study should be read in the light of some limitations — such as the low sample size and the large age difference between study groups when comorbidities were excluded - it still provides relevant insights that could inform about how COVID-19 interacts with pre-existing conditions," note Ernesto Maddaloni, MD, PhD, and Raffaella Buzzetti, MD, both of Sapienza University of Rome, Italy, in an accompanying editorial.

🔎Diabetes Metab Res Rev. Published online March 31, 2020. Article, Editorial.

- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

*Could Tetracyclines Help Fight COVID-19?*

➡️ Currently there is a race against time to identify prophylactic and therapeutic treatments against COVID-19. Until these treatments are developed, tested and mass produced, it might be prudent to look into existing therapies that could be effective against this virus," write Dr. Mahyar Etminan and Dr. Mohit Sodhi of the University of British Columbia, Vancouver, Canada. In email to Reuters Health, Dr. Etminan cited reasons why tetracyclines may have therapeutic value against COVID-19.

➡️ "Tetracyclines have shown to have antiviral activity in other viruses (independent of their antibacterial activity)." They also have "powerful" anti-inflammatory effects "and, of course, inflammation is an important pathological attribute of COVID-19," he explained.

▶️ The anti-inflammatory capabilities of tetracyclines include downregulation of the NFKB pathway as well as a decrease in levels of inflammatory cytokines such as tumor necrosis factor alpha, interleukin-1-beta, and interleukin-6, independent of its antibiotic mechanism, the authors further explain in their letter. These cytokines have been shown to be significantly elevated when SARS-CoV-2 is exposed to lung tissue in addition to exacerbating the pathogenesis of the infection itself, they point out.

⏩ Tetracyclines also have "good absorption in the lungs, where COVID-19 attacks, and are relatively safe, much safer than hydroxychloroquine," Dr. Etminan told Reuters Health.

👉"For all of these reasons, we think there should also be a focus on examining this drug in clinical trials as both a prophylactic agent or treatment in early and late disease," he said.

➡️ Tetracyclines might be potential therapeutic agents for COVID-19 that are "hiding in plain sight," write Dr. Etminan and Dr. Sodhi. "We strongly urge international research groups to consider investigating the potential therapeutic efficacy of tetracycline antibiotics in treating COVID-19."

⏭️ Since the letter was published online April 8, Dr. Etminan said he's received a number of emails from scientists around the world who also think tetracyclines might be helpful in COVID-19 and want to collaborate on future work. Most recently, he heard from an Australian researcher who is considering a trial to study the potential of tetracyclines to protect against novel coronavirus.

Dr. Etminan and Dr. Sodhi have declared no conflicts of interest.

🔎SOURCE: American College of Clinical Pharmacy, Pharmacotherapy, online April 8, 2020.

- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

SARS🦠COV2

Potential Pharnacologic Taegets.

- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

*Colchicine for secondary cardiovascular prevention: a systematic review*

➡️ Despite advancements in medical and interventional therapy, patients with cardiovascular disease (CVD) continue to have residual risk for recurrent cardiovascular events.

▶️ Colchicine has a unique anti‐inflammatory mechanism, which has generated interest in its potential use as a secondary cardiovascular preventive therapy. The objective of this systematic review was to evaluate the evidence for long‐term (≥6 months) colchicine therapy in patients with established CVD.

👉 A search of MEDLINE and Embase from inception to February 2020 was performed. Included were randomized controlled trials or propensity‐score matched observational studies that compared colchicine (at any dose) to placebo or no treatment. Outcomes of interest included any major adverse cardiovascular event, cardiovascular hospitalization, coronary artery restenosis, cardiovascular death, or all‐cause death.

▶️ Five randomized controlled trials were included. The dose of colchicine ranged from 0.5 mg daily to 0.6 mg twice daily, and follow‐up ranged from approximately 6‐36 months. Two trials (one double‐blind and one single‐blind) showed a reduction in composite outcomes of major adverse cardiovascular events.

🔰 One study failed to demonstrate a benefit with colchicine in restenosis or recurrent ischemia after angioplasty; however, it was conducted prior to the routine use of modern percutaneous coronary intervention and medical therapies. In contrast, a more recent trial found that colchicine reduced the rate of in‐stent restenosis in patients who received a bare metal stent.

⏩ Finally, one trial in patients with heart failure with reduced ejection fraction did not observe a benefit in death or heart failure hospitalization with colchicine despite a reduction in inflammatory markers. No trial demonstrated a reduction in cardiovascular or all‐cause death, and most trials showed an increase in the rate of diarrhea with colchicine.

⏺️Overall, colchicine has demonstrated promising results for the secondary prevention of CVD; however, further studies are required to confirm these findings before colchicine can be routinely recommended in practice.

🔎SOURCE: American College of Clinical Pharmacy, April 7, 2020.

- بـرنامـــج تطـــويـــر مهنــة الصيــدلة
https://news.1rj.ru/str/ppdprogram

https://m.facebook.com/story.php?story_fbid=880645802406977&id=413899775748251

*رئيس جامعة العطاء للعلوم والتكنولوجيا يحصل على درجة الاستاذية .. وأسرة الجامعة تتقدم بأحر التهاني والتبريكات..*

إعلام العطاء - خاص :

تستمر جامعة العطاء للعلوم والتكنولوجيا بمفاجئة الوسط العلمي في اليمن ، بين الفينة والاخرى ، وها هي اليوم تحتفي بتتويج رئيس الجامعة البروفيسور محمود البريهي ، بتاج الشرف العلمي الأعلى في اليمن ، وتحتفل بمناسبة حصوله على درجة الأستاذية من جامعة صنعاء .

حيث أقرت جامعة صنعاء ، اليوم الاثنين 20 ابريل 2020 ، ترقية الدكتور / محمود مهيوب محمد البريهي رئيس جامعة العطاء للعلوم والتكنولوجيا ، الأستاذ المشارك بقسم الصيدلانيات تخصص صيدلانيات بكلية الصيدلة (إلى درجة "أستاذ")

وبهذه المناسبة السعيدة تتقدم أسرة جامعة العطاء للعلوم والتكنولوجيا ممثلة برئيس مجلس أمناء الجامعة الدكتور "محمد مهيوب المليكي" بأسمى آيات التهاني والتبريكات لسعادة رئيس الجامعة (أ.د محمود مهيوب البريهي) حصوله على درجة الأستاذية من جامعة صنعاء بقسم الصيدلانيات .

معربا عن فخره واعتزازه بما قدمه البريهي من جهود متواصلة ومضنية في مجال البحث العملي والأكاديمي ، وقال المليكي في برقية التهنئة ، يطيب لي أن أبعث إليكم بأحر التهاني وأصدق الأمنيات بكامل التوفيق في مهامكم السامية لتحقيق تطلعاتكم العلمية والفكرية سائلا المولى عز وجل ان يمنحكم مزيدا من التقدم والنجاح في مستقبلكم العلمي .

هذا ويشار الى ان حصول البريهي على درجة الأستاذية ، إضافة نوعية جديدة للكادر التعليمي المميز الذي تزخر به جامعة العطاء للعلوم والتكنولوجيا ، وخاصة في المرحلة الاستثنائية التي تمر بها اليمن عموما في الوقت الراهن .